Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
Details
Publication Year 2026-04,Volume 14,Issue #3,Page e70222
Journal Title
United European Gastroenterology Journal
Abstract
Celiac disease (CeD) is a chronic autoimmune enteropathy triggered by dietary gluten in genetically predisposed individuals. Currently, a gluten-free diet (GFD) is the only available treatment, being effective in improving mucosal health and symptoms. However, a considerable percentage of celiacs continue to exhibit residual mucosal damage and symptoms. In addition, dietary lapses, and social and nutritional problems pose difficulties with the GFD. Hence, there is an unmet need for new treatments in CeD, driving the development of pharmacologic interventions, with several new drugs in various stages of clinical development. These drugs target distinct steps in the immune pathology of CeD and are intended for patients who continue to experience symptoms despite trying to follow a GFD. Also, the treatment should heal the defective small intestinal mucosa, which is believed to be linked to the risk of long-term complications. This review summarizes emerging CeD therapies, covering trial progress, mechanisms, and potential clinical applications.
Publisher
Wiley
Keywords
Humans; *Celiac Disease/immunology/drug therapy/therapy; Diet, Gluten-Free; *Immune Tolerance/drug effects; Intestinal Mucosa/immunology/pathology/drug effects; Glutens/immunology/adverse effects; Administration, Oral; celiac disease; duodenum; gluten‐free diet; oral tolerance; small‐bowel; transglutaminase
Research Division(s)
Immunology
PubMed ID
42033586
Open Access at Publisher's Site
https://doi.org/10.1002/ueg2.70222
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-04-27 03:52:46
Last Modified: 2026-04-27 03:52:54
An error has occurred. This application may no longer respond until reloaded. Reload 🗙